Telomir Pharmaceuticals, Inc. Earnings Per Share (Diluted)
Telomir Pharmaceuticals, Inc. (TELO) reported Earnings Per Share (Diluted) of -$0.79 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-13
- Telomir Pharmaceuticals, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.79.
- Telomir Pharmaceuticals, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.03.
- Telomir Pharmaceuticals, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.06.
- Telomir Pharmaceuticals, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.03.
- Telomir Pharmaceuticals, Inc. earnings per share, diluted for fiscal 2025 was -$0.33.
- Telomir Pharmaceuticals, Inc. earnings per share, diluted for fiscal 2024 was -$0.56, a 216.67% decline from fiscal 2023.
- Telomir Pharmaceuticals, Inc. earnings per share, diluted for fiscal 2023 was $0.48.
- Telomir Pharmaceuticals, Inc. earnings per share, diluted for fiscal 2022 was -$0.03.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 6 month as first filed | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.79 10-Q · filed 2026-08-13 | -$1.02 10-Q · filed 2026-08-13 | -$0.11 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.15 derived: net income ÷ weighted average shares · filed 2026-08-13 | |||
| 2026-03-31 | -$0.03 10-Q · filed 2026-05-14 | -$0.09 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.12 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.28 derived: net income ÷ weighted average shares · filed 2026-08-13 | |||
| 2025-12-31 | -$0.06 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$0.10 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.33 10-K · filed 2026-03-17 | |||
| 2025-09-30 | -$0.03 10-Q · filed 2025-11-10 | -$0.20 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.27 10-Q · filed 2025-11-10 | -$0.37 derived: net income ÷ weighted average shares · filed 2026-08-13 | |||
| 2025-06-30 | -$0.17 10-Q · filed 2026-08-13 | $0.17 10-Q · filed 2025-08-14 | -$0.24 10-Q · filed 2026-08-13 | $0.24 10-Q · filed 2025-08-14 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.54 derived: net income ÷ weighted average shares · filed 2026-08-13 | |
| 2025-03-31 | -$0.07 10-Q · filed 2026-05-14 | -$0.17 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$0.37 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$0.42 derived: net income ÷ weighted average shares · filed 2026-05-14 | |||
| 2024-12-31 | -$0.10 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$0.30 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$0.35 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$0.56 10-K · filed 2026-03-17 | $0.56 10-K · filed 2025-02-04 | ||
| 2024-09-30 | -$0.20 10-Q · filed 2025-11-10 | -$0.25 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$0.46 10-Q · filed 2025-11-10 | -$0.79 derived: net income ÷ weighted average shares · filed 2025-11-10 | |||
| 2024-06-30 | $0.05 10-Q · filed 2025-08-14 | -$0.05 10-Q · filed 2024-08-13 | $0.26 10-Q · filed 2025-08-14 | -$0.26 10-Q · filed 2024-08-13 | -$0.59 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$0.66 derived: net income ÷ weighted average shares · filed 2025-11-10 | |
| 2024-03-31 | -$0.23 10-Q · filed 2025-05-14 | -$0.55 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$0.62 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$0.68 derived: net income ÷ weighted average shares · filed 2025-11-10 | |||
| 2023-12-31 | -$0.34 derived: net income ÷ weighted average shares · filed 2025-02-04 | -$0.41 derived: net income ÷ weighted average shares · filed 2025-02-04 | -$0.46 derived: net income ÷ weighted average shares · filed 2025-02-04 | $0.48 10-K · filed 2025-02-04 | -$0.45 10-K · filed 2024-03-29 | ||
| 2023-09-30 | -$0.06 10-Q · filed 2024-11-12 | -$0.12 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$0.14 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | -$0.06 10-Q · filed 2024-08-13 | -$0.08 10-Q · filed 2024-08-13 | |||||
| 2023-03-31 | -$0.02 10-Q · filed 2024-05-13 | ||||||
| 2022-12-31 | -$0.03 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |